Insight 2811 Inc. Sells 296 Shares of Danaher Co. (NYSE:DHR)

Insight 2811 Inc. lowered its stake in Danaher Co. (NYSE:DHR) by 16.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,533 shares of the conglomerate’s stock after selling 296 shares during the quarter. Insight 2811 Inc.’s holdings in Danaher were worth $352,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC purchased a new position in shares of Danaher during the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher in the fourth quarter worth $31,000. Finally, Pineridge Advisors LLC raised its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after buying an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.8 %

Shares of DHR stock opened at $212.97 on Tuesday. The business has a 50-day moving average of $216.92 and a 200 day moving average of $238.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The stock has a market capitalization of $152.21 billion, a PE ratio of 40.33, a P/E/G ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm earned $2.09 earnings per share. As a group, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s payout ratio is presently 24.24%.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. The Goldman Sachs Group upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective on the stock in a research report on Friday. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Raymond James reissued a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Finally, Scotiabank initiated coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.